Premier Health Signs Agreement with CB2 Insights to Integrate Medical Cannabis Clinical Decision Support Tool
Data-Driven Technology Firm Begins a First-of-its-Kind Integration with EMR Platform to Provide Nearly 5,000 Physicians and Healthcare Practitioners a Tool to Qualify and Prescribe Medical Cannabis
VANCOUVER, British Columbia, March 27, 2019 – Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce it has initiated integration of CB2 Insights’ (CSE:CBII) medical cannabis Clinical Decision Support (CDS) tool.
The agreement will give the more than 4600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific CDS tool. CB2 Insights’ CDS tool is designed to help incorporate medical cannabis into their patient’s treatment plans. This first-of-its-kind integration in the medical cannabis sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy, all on a patient-specific basis using clinically-validated data.
“For the past 4 years, we have continued to work toward simplifying the process for a physician to gain required understanding amidst the disparate of clinically validate data sets available when considering cannabis as an option within a patient’s treatment plan,” said Prad Sekar, CEO of CB2 Insights. “We are now in a position to benefit from the aggregated and anonymized data gathered from over 300,000 patient visits in a clinical environment to power our CDS tool that will bring clinicians a point-of-care application to help them incorporate cannabis into their practice and create improved access for patients who can benefit from cannabinoid therapy.”
CB2 Insights, through its clinical arm in the US, operates 28 medical cannabis evaluation centers staffed with physicians and healthcare practitioners and creates both access for patients who qualify for medical cannabis as well as a center of excellence to study and understand the clinical outcomes of cannabinoid therapy. CB2 gathers data at the point-of-care in a HIPAA-compliant manner, both aggregated and anonymized, to study trends and outcomes that work to educate and support stakeholders including but not limited to physicians and other healthcare professionals.
“We are dedicated to finding new ways to create value for our physician network,” said Dr. Essam Hamza, CEO of Premier Health. “We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”
As part of the agreement, CB2 will provide the development and continuous maintenance and support of the CDS tool and all related technologies. Premier Health will support by providing access to their software and will engage its network of physicians and other healthcare professionals to assist in the adoption of the CDS tool.
ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD”
Chief Executive Officer
About Premier Health
Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are focused on innovative health care approaches that combine human skill-based expertise with emerging technologies. Premier Health, in conjunction with its subsidiary Cloud Practice, a cloud-based SAAS Electronic Medical Records software company, is developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have a combined ecosystem of 290 clinics, over 3000 licensed practitioners and almost 3 million registered patients. The Premier Health team has deep clinical, operational and financial expertise and a passion for improving healthcare for all patients.
For more information on Juno EMR, please visit www.junoemr.com.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.
For more information please visit www.cb2insights.com.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FOR ADDITIONAL INFORMATION CONTACT:
Premier Health Group Inc.